Views & Analysis 'Free' pricing in the UK: the influence of NICE and NHS Engl... UK drug pricing: just how free is free pricing, these days?
Views & Analysis NICE numbers: trends in recommendations should prompt a revi... Should there be a different review of NICE as part of a successor PPRS?
Views & Analysis Has the UK been best place in the world to invest in life sc... How has the UK compared to its European peers in terms of supporting growth and innovation in the pharmaceutical sector? And with a renegotiation of the PPRS pricing deal imminent, Leela
Views & Analysis Could the PPRS support a changing growth and innovation agen... Has the PPRS delivered on the aim to support the government’s growth and innovation agenda?
Views & Analysis Bureaucracy and duplication: the reality of the PPRS Has the PPRS delivered on the aim of reducing bureaucracy and duplication?
Views & Analysis Improved access? The reality of the PPRS Keeping the UK branded medicines bill within affordable limits - has PPRS delivered?
Oncology BioNTech’s ASCO 2025 oncology advances: New data on bispecif... At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
